Form 4: Corcept Officer Exercises Options, Sells 20,000 Shares

William Guyer, Corcept Therapeutics' Chief Development Officer, executed a pre-planned transaction, exercising stock options and subsequently selling 20,000 common shares.

Summary

• William Guyer, Chief Development Officer of Corcept Therapeutics Inc. (CORT), reported a transaction on January 6, 2026.
• The transaction involved the exercise of 20,000 stock options at an exercise price of $21.65 per share.
• Concurrently, 20,000 shares of common stock were sold at a weighted average price of $35.1828 per share, with actual sale prices ranging from $34.96 to $35.50.
• This transaction was conducted under a Rule 10b5-1 trading plan adopted on November 27, 2024.
• Following these transactions, Mr. Guyer directly owns 1,235 shares of common stock and 250,000 stock options.

Sentiment

Score: 6

Explanation: The transaction is a routine, pre-planned insider sale under a 10b5-1 plan, which typically has a neutral to slightly positive sentiment as it demonstrates the officer realizing value from their compensation. The significant profit margin between exercise and sale price is positive for the individual, but the sale itself is a slight negative for general investor sentiment, hence a neutral-to-slightly-positive score.

Positives

• The officer realized a significant profit from the option exercise and subsequent sale, with the sale price ($35.1828) substantially higher than the exercise price ($21.65).
• The transaction was executed under a pre-arranged 10b5-1 plan, indicating a planned rather than reactive sale.

Negatives

• An officer selling a significant number of shares, even if pre-planned, can sometimes be perceived as a slight negative signal by investors.

Future Outlook

This Form 4 filing pertains to an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are common across all industries. They provide transparency into executive stock ownership and trading activities but typically do not reflect broader industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: Provides transparency into executive stock transactions, but unlikely to have a significant direct impact on share price given the pre-planned nature.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Key Dates

Keywords

Corcept Therapeutics, CORT, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, Officer Transaction, Equity Sale, William Guyer, Chief Development Officer